Latest News and Press Releases

Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory...

Third asset to advance into clinical trials, validating broad potential of Launch-iT platformAll subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential...

June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical...

Curevo enrolls first participants in Phase 2 extension trial with target enrollment of 640 healthy adults aged 50 and over.

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 monthsSurvival has currently reached plateau, with 34% (7/20) of...

AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025– Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology...

The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic.  MUNICH, GERMANY, May 20, 2025 – Tubulis today...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by...

DURHAM, N.C. and GRAND RAPIDS, Mich., May 19, 2025 (GLOBE NEWSWIRE) -- PhotoniCare Inc., a medical device company dedicated to delivering innovation to frontline care that demonstrably enhances...